- Investing Ideas
- U.K. Pharmaceuticals & Biotech Undervalued over 20% based on DCF
U.K. Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Results
4
Companies which are undervalued more than 20% based on the Discounted Cash Flow valuation.
4 companies
AstraZeneca
Market Cap: UK£208.4b
A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
AZN
UK£134.34
7D
-3.5%
1Y
27.0%
Haleon
Market Cap: UK£29.0b
Engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.
HLN
UK£3.27
7D
-4.9%
1Y
-21.1%
Oxford Biomedica
Market Cap: UK£744.9m
A contract development and manufacturing organization, focuses on delivering therapies to patients worldwide.
OXB
UK£6.16
7D
-0.3%
1Y
87.5%
Bioventix
Market Cap: UK£86.7m
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide.
BVXP
UK£16.60
7D
-0.9%
1Y
-42.8%